Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2761–2784 of 13,629 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Neoplasms
Interventions: MST-997; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: New York, New York • Cleveland, Ohio • Nashville, Tennessee

Conditions: Acne Vulgaris
Interventions: Study of humoral immunity; Diagnostic Test
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Breast Cancer, Cancer, Healthy, Emotions
Interventions: Expressive Writing; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Timeline: 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Stage IV Melanoma
Interventions: LC beads loaded with Doxorubicin; Device
Lead sponsor: Robert C. Martin; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Louisville, Kentucky • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Atopic Dermatitis, Eczema, DNA
Interventions: DNA reports, Information reports; Behavioral
Lead sponsor: Studies&Me; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Breast Cancer
Interventions: Capecitabine; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Dermatitis
Interventions: Dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 129
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 100 more

Conditions: Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
Interventions: BNT323, BNT327; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 29
States / cities: Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 19 more

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus Cream 1%; Drug
Lead sponsor: Novartis; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 160 participants
Timeline: 2004 – 2005
U.S. locations: 0
States / cities: Not listed

Conditions: Neoplasms, Breast
Interventions: Not listed
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: Newark, Delaware • Plantation, Florida • Charleston, South Carolina + 1 more

Conditions: Pruritus, Burns
Interventions: Serlopitant, Placebo; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Gainesville, Florida + 4 more

Conditions: Systemic Sclerosis (SSc)
Interventions: Apollo Neuro Device, Sham device; Device
Lead sponsor: Robyn T. Domsic, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: New Orleans, Louisiana • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 1 more

Conditions: Healthy, Actinic Keratosis
Interventions: PEP005 Gel; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Breast Cancer
Interventions: capecitabine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 3
States / cities: Annapolis, Maryland • Baltimore, Maryland • Boston, Massachusetts

Conditions: Malignant Melanoma
Interventions: Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2031
U.S. locations: 3
States / cities: San Diego, California • Memphis, Tennessee • Houston, Texas

Conditions: Wart, Common Wart, Verruca Vulgaris, Verruca Plantaris, Plantar Wart
Interventions: duct tape occlusion therapy; Device
Lead sponsor: Minneapolis Veterans Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Inflammatory Acne
Interventions: LYS006 20 mg, LYS006 2 mg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 7
States / cities: Fremont, California • Santa Monica, California • Hialeah, Florida + 4 more

Conditions: Advanced Breast Cancer, Early Breast Cancer
Interventions: ZOLADEX; Drug
Lead sponsor: TerSera Therapeutics LLC; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 28
States / cities: Hot Springs, Arkansas • Washington D.C., District of Columbia • Miami, Florida + 25 more

Conditions: Metastatic Breast Cancer
Interventions: ABI-007, Bevacizumab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 20
States / cities: Melbourne, Florida • Ocoee, Florida • Niles, Illinois + 17 more

Conditions: Melanoma, Metastatic Melanoma, Mucosal Melanoma
Interventions: Peptide Vaccine (LPV7) + Tetanus peptide, PolyICLC, Resiquimod, IFA; Biological · Other
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 2
States / cities: Houston, Texas • Charlottesville, Virginia

Conditions: Breast Cancer
Interventions: Full Field Digital Mammography, Screen Film Mammography; Diagnostic Test
Lead sponsor: American College of Radiology Imaging Network; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 49,528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 31
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 23 more

Conditions: Psoriasis
Interventions: Methotrexate; Drug
Lead sponsor: medac GmbH; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor
Interventions: HMBD-002, Pembrolizumab; Drug
Lead sponsor: Hummingbird Bioscience; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 3 more

Conditions: Chronic Idiopathic Urticaria
Interventions: etanercept, placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

Study Evaluating MST-997 in Advanced Malignant Solid Tumors

Acne Vulgaris Related Microbiology and Serology

Emotion Regulation and Cancer Caregiving

LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma

Using a Telemedicine Approach in a Genome-wide Association Study of Atopic Dermatitis - Searching for Novel Biomarkers in Clinically Relevant Phenotypes

Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis

Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer

Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury

The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life

PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects

Capecitabine in Treating Patients With Metastatic Breast Cancer

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts

Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

Digital Mammography Screening Trial (ACRIN6652)

Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen

A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors

Etanercept for the Treatment of Chronic Urticaria